Jaime A Espinoza
Overview
Explore the profile of Jaime A Espinoza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
591
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Espinoza J, Kanellis D, Saproo S, Leal K, Martinez J, Bartek J, et al.
Nucleic Acids Res
. 2024 Feb;
52(8):4151-4166.
PMID: 38340348
In cancer therapy, DNA intercalators are mainly known for their capacity to kill cells by inducing DNA damage. Recently, several DNA intercalators have attracted much interest given their ability to...
2.
Kanellis D, Zisi A, Skrott Z, Lemmens B, Espinoza J, Kosar M, et al.
Cell Death Differ
. 2023 May;
30(7):1666-1678.
PMID: 37142656
Drug repurposing is a versatile strategy to improve current therapies. Disulfiram has long been used in the treatment of alcohol dependency and multiple clinical trials to evaluate its clinical value...
3.
Gromova I, Espinoza J, Grauslund M, Santoni-Rugiu E, Moller Talman M, van Oostrum J, et al.
Cells
. 2021 Oct;
10(10).
PMID: 34685748
Triple-negative breast cancer (TNBC) is a subtype of breast cancer that comprises various disease entities, all of which share a set of common features: a lack of expression of the...
4.
Kanellis D, Espinoza J, Zisi A, Sakkas E, Bartkova J, Katsori A, et al.
Sci Adv
. 2021 Aug;
7(32).
PMID: 34348895
Eukaryotic initiation factor 4A-III (eIF4A3), a core helicase component of the exon junction complex, is essential for splicing, mRNA trafficking, and nonsense-mediated decay processes emerging as targets in cancer therapy....
5.
Rosa L, Lobos-Gonzalez L, Munoz-Durango N, Garcia P, Bizama C, Gomez N, et al.
Mol Oncol
. 2020 Dec;
14(11):2834-2852.
PMID: 33326125
Gallbladder stones (cholecystolithiasis) are the main risk factor for gallbladder cancer (GBC), a lethal biliary malignancy with poor survival rates worldwide. Gallbladder stones are thought to damage the gallbladder epithelium...
6.
Garcia P, Bizama C, Rosa L, Espinoza J, Weber H, Cerda-Infante J, et al.
Biol Res
. 2020 Apr;
53(1):13.
PMID: 32293552
Background: Gallbladder cancer (GBC) is the most common tumor of the biliary tract. The incidence of GBC shows a large geographic variability, being particularly frequent in Native American populations. In...
7.
Garcia P, Rosa L, Vargas S, Weber H, Espinoza J, Suarez F, et al.
Cancers (Basel)
. 2020 Mar;
12(4).
PMID: 32218280
Gallbladder cancer is an aggressive disease with late diagnosis and no efficacious treatment. The Hippo-Yes-associated protein 1 (YAP1) signaling pathway has emerged as a target for the development of new...
8.
Espinoza J, Zisi A, Kanellis D, Carreras-Puigvert J, Henriksson M, Huhn D, et al.
Cell Death Differ
. 2019 Jul;
27(2):773-789.
PMID: 31285544
Pharmacological inhibition of ribosome biogenesis is a promising avenue for cancer therapy. Herein, we report a novel activity of the FDA-approved antimalarial drug amodiaquine which inhibits rRNA transcription, a rate-limiting...
9.
Jabeen S, Espinoza J, Torland L, Zucknick M, Kumar S, Haakensen V, et al.
Oncoimmunology
. 2019 Feb;
8(2):e1537691.
PMID: 30713794
Cancers elicit an immune response by modifying the microenvironment. The immune system plays a pivotal role in cancer recognition and eradication. While the potential clinical value of infiltrating lymphocytes at...
10.
Espinoza J, Riquelme I, Sagredo E, Rosa L, Garcia P, Bizama C, et al.
Histopathology
. 2018 Dec;
74(4):597-607.
PMID: 30565710
Aims: Gallbladder cancer (GBC) is an aggressive tumour that is usually diagnosed at advanced stages and is characterised by a poor prognosis. Using public data of normal human tissues, we...